

How Automated Detection Gave a Patient a Second Chance 2 Years After Initial Evaluation

Success Story: Mosaic Life Care, Saint Joseph, MO

Highlights:

- Over nine months, LungTraX Detect CT analyzed 3,233 chest CTs and identified 553 patients who met the team's emphysema destruction criteria.
- A patient with a single CV+ target in 2023 was automatically re-identified by Lung TraX Detect CT two years later, revealing a new CV- target that was then successfully treated with Zephyr Valves.

Pioneering the Future of Early Emphysema Identification

In January 2025, Mosaic Life Care partnered with Pulmonx to pilot LungTraX Detect CT, an AI-driven software designed to automatically analyze Lung Cancer Screening and Chest CT scans to identify patients with severe emphysema who may benefit from Zephyr[®] Valve treatment.

Over a nine-month pilot, 3,233 scans were analyzed. Among them, 553 patients met emphysema destruction score thresholds, generating 53 new StratX[®] Reports for patients who may have otherwise gone unrecognized as candidates for bronchoscopic lung volume reduction.

A Patient's Second Chance

The first LungTraX Detect-identified patient treated at Mosaic exemplifies the impact of an automated, CT-based method of patient identification.

The patient was originally evaluated for Zephyr Valve therapy in 2023 and found to have a single right middle lobe target, which was confirmed CV+ upon Chartis assessment. The patient was discharged and returned to standard pulmonary care.

Two years later, on July 14, 2025, the same patient underwent a routine Lung Cancer Screening CT. Thanks to LungTraX Detect CT, this scan was automatically identified as meeting destruction criteria and escalated to the Mosaic care team for further review.




**DESTRUCTION: 55% AT -910HU AND
24% AT -950HU. FISSURE SCORE: 82%**



JULY 22, 2025:

Mosaic's care team recognized the patient's name and requested a StratX® Report directly through the platform using the "Send to StratX" button. The analysis revealed a secondary treatment target – the left lower lobe, showing 55% destruction at -910 HU and 24% at -950 HU.



AUGUST 2025:

With this new insight, the team reengaged the patient, confirmed the left fissure as CV-, and determined candidacy for valve treatment.



AUGUST 25, 2025:

The patient was successfully treated with four Zephyr Valves in the left lower lobe.

Transforming Care Through Intelligent Detection

Mosaic Life Care's pilot demonstrates how integrating LungTraX™ Detect CT into routine imaging workflows enables:

- Automated identification of undiagnosed emphysema patients
- Re-engagement of prior candidates with disease progression
- Expansion of the treatable population, driving earlier and more equitable access to therapy

With LungTraX Detect CT Mosaic Life Care has taken a leading step in redefining how health systems uncover and manage patients living with advanced emphysema – turning missed opportunities into life-changing second chances.

Learn more about LungTraX Detect CT by contacting your local Pulmonx representative.

Important Safety Information: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone; or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, lobectomy, or pleurodesis on the target lung side; Congestive heart failure or recent myocardial infarction; FEV1 <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.

Caution: Federal law restricts this device to sale by or on the order of a physician.

Important Safety Information: The Chartis® System is indicated for use by bronchoscopists during a bronchoscopy in adult patients with emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD), in a bronchoscopy suite. The system, composed of the Chartis Catheter and Chartis Console, is designed to measure pressure and flow in order to calculate resistance to airflow and quantify collateral ventilation in isolated lung compartments. The Chartis Catheter is used through the working channel of a bronchoscope and connects to the Chartis Console. The Chartis Console is capital equipment that is reusable and displays the patient information. The Chartis System is contraindicated in the presence of active infection or major bleeding diathesis. There are no known interfering substances. Use is restricted to a trained physician. Prior to use, please reference the Chartis System Instructions for Use/ User Manual for more information on indications, contraindications, warnings, all precautions, and adverse events.

Caution: Federal law restricts this device to sale by or on the order of a physician.